The relationship between hormone replacement therapy (HRT) and cardiovascular disease is more nuanced than a simple yes or no. Here is what current science says and why timing matters more than most people realize. Evidence-Based Review · Updated 2026
In this article
- The short answer: timing is everything
- Heart attack and stroke risk
- Blood clots and vein health
- How HRT affects your cholesterol
- Lp(a): a hidden heart risk factor HRT may help
- What this means for your care
The short answer: timing is everything
Major medical organizations including the US Preventive Services Task Force, the American Heart Association, and the North American Menopause Society agree on one thing: HRT should not be prescribed solely for the purpose of preventing heart disease or dementia. That is the guideline consensus, and it is reasonable.
But the science underneath that recommendation is far more layered. The most important variable turns out to be when you start hormone therapy relative to menopause, not simply whether you use it at all. This concept is known as the “timing hypothesis,” and it has substantial research support.
Key insight
Women who begin HRT within 10 years of menopause or before age 60 appear to have meaningfully different cardiovascular outcomes than women who begin it a decade or more later.
Heart attack and stroke risk
Much of the confusion around HRT and heart disease comes from one landmark study: the Women’s Health Initiative (WHI), which enrolled women with an average age of 63, many of whom were well past the menopausal transition. That study found no heart benefit and some increased risk.
But a more recent Cochrane review, which pooled data from multiple randomized trials, found something strikingly different when women were grouped by timing:
48% Reduction in coronary heart disease risk for women starting HRT within 10 years of menopause
30% Reduction in all-cause mortality for early initiators
No benefit for women starting HRT more than 10 years after menopause, with increased stroke and clot risk
A Finnish registry study of nearly 500,000 women supported this further: women who began estradiol-based HRT before age 60 had a substantially lower rate of cardiovascular death than those who started later.
What about stroke specifically?
Oral estrogen does appear to raise stroke risk in the general population of HRT users, but the picture changes with both age and delivery method. In women aged 50 to 59, stroke event rates were essentially identical between estrogen users and those on placebo. And transdermal estrogen (meaning topical patches or gels) does not appear to increase stroke risk at all based on current evidence.
Blood clots and vein health
Oral estrogen meaningfully increases the risk of venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism. A meta-analysis of 15 observational studies found oral estrogen was associated with 63% higher VTE risk compared to the transdermal form.
ⓘ Route of delivery matters
Transdermal estrogen bypasses the liver and does not appear to raise clotting risk. A 2026 review in the New England Journal of Medicine confirmed this, and found that when transdermal estrogen is combined with micronized progesterone (bioidentical), no increase in thrombotic risk is apparent. This distinction is clinically significant for women with elevated cardiovascular risk.
How HRT affects your cholesterol
Estrogen therapy produces well-characterized changes to the lipid panel. The general pattern with oral estrogen is:
| Lipid marker | Effect of oral estrogen | Transdermal estrogen |
|---|---|---|
| LDL cholesterol | Decreased up to 20% | Similar, smaller magnitude |
| HDL cholesterol | Increased up to 15% | Similar, smaller magnitude |
| Triglycerides | Can increase significantly | Does not raise triglycerides |
One important note: if you already have elevated triglycerides, oral estrogen can drive them dramatically higher, potentially triggering pancreatitis. Transdermal estrogen does not carry this risk, which is one reason route of administration matters so much in individualized care.
Progestins (IUDs, norethindrone), which are synthetic forms of progesterone, tend to blunt the HDL increase that estrogen provides. Micronized progesterone appears to have a more favorable support of HDLs.
Lp(a): a hidden heart risk factor HRT may help
Lipoprotein(a), or Lp(a), is an independent cardiovascular risk factor that most standard lipid panels do not even measure (However, we do). It is largely genetically determined and notoriously difficult to lower with conventional therapies. HRT is one of the few available interventions that substantially reduces Lp(a).
20% Average Lp(a) reduction across 24 randomized controlled trials
Up to 44% Lp(a) reduction seen with some oral estrogen formulations
Oral estrogen is significantly more effective than transdermal for Lp(a) lowering. Transdermal estrogen has minimal effect on Lp(a) levels.
Important caveat:
Whether reducing Lp(a) through HRT translates into fewer cardiovascular events has not yet been proven. This is an active area of research. But given that Lp(a) is a significant independent risk factor and very few therapies lower it substantially, this effect of oral estrogen is clinically worth noting, particularly in women with elevated Lp(a).
What this means for your care
If you are approaching or in the early years of menopause, here is the practical picture from the current evidence:
HRT initiated within 10 years of menopause or before age 60 carries a meaningfully different cardiovascular risk profile than HRT started much later. For women in the early window who have vasomotor symptoms such as hot flashes and night sweats, the evidence does not support increased heart disease risk and may suggest some protection. For women starting HRT after age 70, current data show increased cardiovascular risk and the risk-benefit calculation shifts substantially.
Route of delivery is not a footnote. Transdermal estrogen avoids the stroke risk and triglyceride increase associated with oral forms, and does not raise clotting risk. The choice between oral and transdermal should be individualized based on your personal risk factors.
Lp(a) testing is underutilized in most conventional practices. If you have a strong family history of early heart disease or have never had your Lp(a) measured, it is worth asking about, particularly when weighing the form of HRT that may best serve your cardiovascular health.
HRT is not a one-size-fits-all intervention, and neither is cardiovascular risk. A comprehensive, individualized evaluation is the only way to determine what is right for you.
🔎 References
This article draws on the 2022 USPSTF systematic review, the 2015 Cochrane meta-analysis of HRT for cardiovascular prevention, a 2025 WHI secondary analysis (JAMA Internal Medicine), a Finnish nationwide registry study (n=498,105), a 2026 NEJM review on thrombotic risk, and a meta-analysis of 24 RCTs examining Lp(a) effects of hormone therapy. All cited findings are from peer-reviewed sources.
Ready to discuss HRT and your heart health?
Our team at VIS takes a whole-person, evidence-based approach to menopause care, including personalized cardiovascular risk evaluation.
